Medicover Valuation
Is MCOV B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MCOV B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MCOV B (SEK189.6) is trading below our estimate of fair value (SEK346.87)
Significantly Below Fair Value: MCOV B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MCOV B?
Other financial metrics that can be useful for relative valuation.
What is MCOV B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €2.52b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.9x |
Enterprise Value/EBITDA | 20.4x |
PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does MCOV B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 15.8x | ||
DEDI Dedicare | 7.5x | n/a | SEK 665.6m |
EKTA B Elekta | 23.1x | 17.8% | SEK 26.2b |
ATT Attendo | 18.6x | 23.2% | SEK 7.3b |
AMBEA Ambea | 14x | 13.3% | SEK 7.7b |
MCOV B Medicover | 109.1x | 38.6% | SEK 28.5b |
Price-To-Earnings vs Peers: MCOV B is expensive based on its Price-To-Earnings Ratio (109.1x) compared to the peer average (15.8x).
Price to Earnings Ratio vs Industry
How does MCOV B's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: MCOV B is expensive based on its Price-To-Earnings Ratio (109.1x) compared to the European Healthcare industry average (19.1x).
Price to Earnings Ratio vs Fair Ratio
What is MCOV B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 109.1x |
Fair PE Ratio | 39.2x |
Price-To-Earnings vs Fair Ratio: MCOV B is expensive based on its Price-To-Earnings Ratio (109.1x) compared to the estimated Fair Price-To-Earnings Ratio (39.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 193.00 | SEK 202.95 +5.2% | 8.1% | SEK 216.63 | SEK 179.81 | n/a | 3 |
Sep ’25 | SEK 187.80 | SEK 205.30 +9.3% | 8.8% | SEK 220.21 | SEK 179.80 | n/a | 3 |
Aug ’25 | SEK 187.40 | SEK 207.63 +10.8% | 9.3% | SEK 222.20 | SEK 180.31 | n/a | 3 |
Jul ’25 | SEK 192.60 | SEK 195.12 +1.3% | 8.2% | SEK 211.95 | SEK 173.48 | n/a | 3 |
Jun ’25 | SEK 196.80 | SEK 199.13 +1.2% | 8.2% | SEK 220.14 | SEK 180.18 | n/a | 3 |
May ’25 | SEK 175.00 | SEK 199.13 +13.8% | 8.2% | SEK 220.14 | SEK 180.18 | n/a | 3 |
Apr ’25 | SEK 138.00 | SEK 190.26 +37.9% | 5.4% | SEK 203.56 | SEK 178.75 | n/a | 3 |
Mar ’25 | SEK 142.50 | SEK 190.26 +33.5% | 5.4% | SEK 203.56 | SEK 178.75 | n/a | 3 |
Feb ’25 | SEK 170.60 | SEK 201.25 +18.0% | 9.0% | SEK 220.52 | SEK 171.59 | n/a | 4 |
Jan ’25 | SEK 150.10 | SEK 201.25 +34.1% | 9.0% | SEK 220.52 | SEK 171.59 | n/a | 4 |
Dec ’24 | SEK 143.20 | SEK 213.90 +49.4% | 10.6% | SEK 236.19 | SEK 177.15 | n/a | 4 |
Nov ’24 | SEK 126.80 | SEK 223.16 +76.0% | 11.0% | SEK 248.27 | SEK 183.14 | n/a | 4 |
Oct ’24 | SEK 143.70 | SEK 223.16 +55.3% | 11.0% | SEK 248.27 | SEK 183.14 | n/a | 4 |
Sep ’24 | SEK 155.40 | SEK 223.16 +43.6% | 11.0% | SEK 248.27 | SEK 183.14 | SEK 187.80 | 4 |
Aug ’24 | SEK 157.50 | SEK 219.66 +39.5% | 10.5% | SEK 240.64 | SEK 180.48 | SEK 187.40 | 4 |
Jul ’24 | SEK 163.70 | SEK 224.27 +37.0% | 12.0% | SEK 251.43 | SEK 179.69 | SEK 192.60 | 4 |
Jun ’24 | SEK 167.70 | SEK 219.29 +30.8% | 10.8% | SEK 244.17 | SEK 180.49 | SEK 196.80 | 4 |
May ’24 | SEK 169.10 | SEK 214.01 +26.6% | 9.7% | SEK 232.10 | SEK 179.95 | SEK 175.00 | 4 |
Apr ’24 | SEK 168.00 | SEK 205.00 +22.0% | 15.5% | SEK 227.89 | SEK 150.37 | SEK 138.00 | 4 |
Mar ’24 | SEK 178.80 | SEK 200.94 +12.4% | 15.1% | SEK 225.58 | SEK 148.85 | SEK 142.50 | 4 |
Feb ’24 | SEK 179.30 | SEK 178.04 -0.7% | 19.4% | SEK 236.97 | SEK 150.04 | SEK 170.60 | 4 |
Jan ’24 | SEK 139.70 | SEK 178.04 +27.4% | 19.4% | SEK 236.97 | SEK 150.04 | SEK 150.10 | 4 |
Dec ’23 | SEK 142.20 | SEK 178.04 +25.2% | 19.4% | SEK 236.97 | SEK 150.04 | SEK 143.20 | 4 |
Nov ’23 | SEK 134.70 | SEK 199.05 +47.8% | 17.4% | SEK 241.32 | SEK 153.09 | SEK 126.80 | 4 |
Oct ’23 | SEK 119.70 | SEK 193.35 +61.5% | 15.3% | SEK 229.64 | SEK 152.40 | SEK 143.70 | 4 |
Sep ’23 | SEK 131.30 | SEK 193.35 +47.3% | 15.3% | SEK 229.64 | SEK 152.40 | SEK 155.40 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.